drugset / Trial / NCT03619655
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Phase 1
Terminated
3 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT.
Timeline
- Start
- 2019-11-15
- Primary completion
- 2022-11-14
- Completion
- 2022-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-DCFPyL | Diagnostic / imaging agent | 333 mbq | Intravenous |
| Subject | Sodium Fluoride F-18 | Diagnostic / imaging agent | 5 mbq | Intravenous |